SG11201909094VA - 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same - Google Patents
4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including sameInfo
- Publication number
- SG11201909094VA SG11201909094VA SG11201909094VA SG11201909094VA SG 11201909094V A SG11201909094V A SG 11201909094VA SG 11201909094V A SG11201909094V A SG 11201909094VA SG 11201909094V A SG11201909094V A SG 11201909094VA
- Authority
- SG
- Singapore
- Prior art keywords
- salt
- pharmaceutical composition
- formulation including
- hepatitis
- including same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME An object of the present invention is to provide a compound or a salt thereof having anti-HBV activity, a pharmaceutical composition, an anti-hepatitis B virus agent, a production inhibitor of DNA of a hepatitis B virus, and a production or secretion inhibitor of a hepatitis B surface antigen. According to the present invention, provided are a compound represented by General Formula [1] or a salt thereof: (in the formula, R 1 represents a benzothiazolyl group which may be substituted (in which a carbon atom constituting the 6-membered ring of the benzothiazolyl group of R 1 is bonded to the nitrogen atom of the pyridone ring); R 2 represents a C 2-6 alkenyl group which may be substituted, or the like; and R 3 represents a hydrogen atom or the like). [No available figure]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017069837 | 2017-03-31 | ||
JP2017166413 | 2017-08-31 | ||
PCT/JP2018/013580 WO2018181883A1 (en) | 2017-03-31 | 2018-03-30 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909094VA true SG11201909094VA (en) | 2019-11-28 |
Family
ID=63676176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909094V SG11201909094VA (en) | 2017-03-31 | 2018-03-30 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same |
Country Status (15)
Country | Link |
---|---|
US (1) | US11161830B2 (en) |
EP (1) | EP3604301B1 (en) |
JP (1) | JP6813665B2 (en) |
KR (1) | KR20190122762A (en) |
CN (1) | CN110475775B (en) |
AU (1) | AU2018246563B2 (en) |
BR (1) | BR112019020401A2 (en) |
CA (1) | CA3058111A1 (en) |
ES (1) | ES2895023T3 (en) |
MX (1) | MX2019011762A (en) |
RU (1) | RU2019130519A (en) |
SG (1) | SG11201909094VA (en) |
TW (1) | TW201841911A (en) |
WO (1) | WO2018181883A1 (en) |
ZA (1) | ZA201906451B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
JP6904970B2 (en) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Hepatitis B antiviral agent |
MX2020002191A (en) | 2017-08-28 | 2020-10-05 | Enanta Pharm Inc | Hepatitis b antiviral agents. |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
JP2022507724A (en) | 2018-11-21 | 2022-01-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | Functionalized heterocycle as an antiviral agent |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
CN117136187A (en) * | 2021-06-24 | 2023-11-28 | 上海齐鲁制药研究中心有限公司 | Novel anti-hepatitis B compound |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5980665A (en) | 1982-10-29 | 1984-05-10 | Toyama Chem Co Ltd | 4-oxo-1,4-dihydronicotinic acid derivative |
DE3338846A1 (en) * | 1982-10-29 | 1984-05-03 | Toyama Chemical Co. Ltd., Tokyo | NEW 4-OXO-1,4-DIHYDRONICOTINE ACID DERIVATIVES AND SALTS THEREOF, METHOD FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS WITH A CONTENT THEREOF |
GB8509086D0 (en) | 1985-04-09 | 1985-05-15 | Fujisawa Pharmaceutical Co | Dihydronicotinic acid derivatives |
JPH0261947A (en) | 1988-08-26 | 1990-03-01 | Matsushita Electric Ind Co Ltd | Image display device |
DE3934082A1 (en) | 1989-10-12 | 1991-04-18 | Bayer Ag | CHINOLON CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS AN ANTIVIRAL AGENT |
DE19817265A1 (en) | 1998-04-18 | 1999-10-21 | Bayer Ag | Treating hepatitis B using new or known dihydropyrimidine derivative antiviral agents |
US6777420B2 (en) * | 2001-06-15 | 2004-08-17 | Microbiotix, Inc. | Heterocyclic antibacterial compounds |
CN1465567A (en) | 2002-06-21 | 2004-01-07 | 陈依军 | Dihydropyridone derivative and use thereof |
CN101328171A (en) * | 2007-06-18 | 2008-12-24 | 张中能 | Bromophenyl-substituted thiazole dihydropyrimidine |
ES2826273T3 (en) | 2008-09-24 | 2021-05-17 | Melinta Subsidiary Corp | Process for the manufacture of quinolone compounds |
WO2010110231A1 (en) * | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | Substituted 3-hydroxy-4-pyridone derivative |
US9024032B2 (en) | 2010-03-04 | 2015-05-05 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
CN103992290B (en) | 2013-05-14 | 2016-07-06 | 中国医学科学院医药生物技术研究所 | Diarylethene structurally similar compounds and its preparation method and application |
CN107207505B (en) * | 2015-02-11 | 2018-12-14 | 豪夫迈·罗氏有限公司 | Treat and prevent hepatitis b virus infected 2- oxo -6,7- dihydrobenzo [a] quinolizine -3- formic acid derivates |
JP6598974B2 (en) | 2015-07-21 | 2019-10-30 | エフ.ホフマン−ラ ロシュ アーゲー | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection |
US10308642B2 (en) | 2015-10-05 | 2019-06-04 | Fujifilm Toyama Chemical Co., Ltd. | Anti-hepatitis B virus agent |
-
2018
- 2018-03-30 WO PCT/JP2018/013580 patent/WO2018181883A1/en active Application Filing
- 2018-03-30 SG SG11201909094V patent/SG11201909094VA/en unknown
- 2018-03-30 MX MX2019011762A patent/MX2019011762A/en unknown
- 2018-03-30 CA CA3058111A patent/CA3058111A1/en not_active Abandoned
- 2018-03-30 JP JP2019510237A patent/JP6813665B2/en active Active
- 2018-03-30 RU RU2019130519A patent/RU2019130519A/en not_active Application Discontinuation
- 2018-03-30 CN CN201880022663.XA patent/CN110475775B/en active Active
- 2018-03-30 TW TW107111143A patent/TW201841911A/en unknown
- 2018-03-30 BR BR112019020401A patent/BR112019020401A2/en not_active IP Right Cessation
- 2018-03-30 KR KR1020197028352A patent/KR20190122762A/en not_active Application Discontinuation
- 2018-03-30 ES ES18775249T patent/ES2895023T3/en active Active
- 2018-03-30 AU AU2018246563A patent/AU2018246563B2/en not_active Ceased
- 2018-03-30 EP EP18775249.8A patent/EP3604301B1/en active Active
-
2019
- 2019-09-26 US US16/583,916 patent/US11161830B2/en active Active
- 2019-09-30 ZA ZA2019/06451A patent/ZA201906451B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2019011762A (en) | 2019-12-02 |
EP3604301A4 (en) | 2020-02-05 |
AU2018246563B2 (en) | 2020-07-30 |
CN110475775B (en) | 2023-05-09 |
JPWO2018181883A1 (en) | 2020-01-16 |
BR112019020401A2 (en) | 2020-04-22 |
US11161830B2 (en) | 2021-11-02 |
AU2018246563A1 (en) | 2019-10-17 |
TW201841911A (en) | 2018-12-01 |
EP3604301A1 (en) | 2020-02-05 |
KR20190122762A (en) | 2019-10-30 |
US20200017459A1 (en) | 2020-01-16 |
CN110475775A (en) | 2019-11-19 |
RU2019130519A3 (en) | 2021-04-30 |
JP6813665B2 (en) | 2021-01-13 |
RU2019130519A (en) | 2021-04-30 |
WO2018181883A1 (en) | 2018-10-04 |
ES2895023T3 (en) | 2022-02-17 |
ZA201906451B (en) | 2021-01-27 |
CA3058111A1 (en) | 2018-10-04 |
EP3604301B1 (en) | 2021-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909094VA (en) | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | |
PH12018550201A1 (en) | Hepatitis b antiviral agents | |
EA038122B9 (en) | Hepatitis b virus surface antigen inhibitor | |
MX2018010805A (en) | Hepatitis b antiviral agents. | |
PH12016501631A1 (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
WO2017163078A8 (en) | 1-cyano-pyrrolidine derivatives as dub inhibitors | |
MX2018010010A (en) | Tetracyclic pyridone compounds as antivirals. | |
GEP20227373B (en) | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
JP2016536363A5 (en) | ||
NZ631762A (en) | 5-membered heteroaryls and their use as antiviral agents | |
JP2016536364A5 (en) | ||
TN2014000427A1 (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
MY144895A (en) | Macrocylic inhibitors of hepatitis c virus | |
MX2020002191A (en) | Hepatitis b antiviral agents. | |
NZ631738A (en) | (hetero) arylacetamide derivatives as antiretroviral agents | |
MX2016015960A (en) | Herbicidal propynyl-phenyl compounds. | |
GEP20227374B (en) | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) | |
MX2019013815A (en) | Hepatitis b virus surface antigen inhibitor. | |
MX2009012613A (en) | Heteroaryl substituted thiazoles and their use as antiviral agents. | |
PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
MX2016005993A (en) | Biscationic and triscationic amphiles as antimicrobial agents. | |
SG11201901619WA (en) | Bicyclic nitrogenated heterocyclic compound | |
TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
SA112330457B1 (en) | Phenyl-isoxazol derivatives and preparation process thereof | |
FR2894578B1 (en) | HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |